Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $16.43, but opened at $16.81. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $16.50, with a volume of 1,786 shares changing hands.
Analyst Upgrades and Downgrades
Separately, William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th.
Read Our Latest Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 1.0%
The firm has a fifty day simple moving average of $16.75 and a two-hundred day simple moving average of $16.81.
Institutional Investors Weigh In On Telix Pharmaceuticals Limited American Depositary Shares
An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. Private Advisor Group LLC purchased a new position in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,140 shares of the company's stock, valued at approximately $170,000.
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
